Rani E George

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. doi request reprint Tumor histology during induction therapy in patients with high-risk neuroblastoma
    Rani E George
    Department of Pediatric Hematology and Oncology, Dana Farber Cancer Institute and Children s Hospital, Boston, MA 02115, USA
    Pediatr Blood Cancer 59:506-10. 2012
  2. pmc Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma
    Idoia Garcia
    Developmental Tumor Biology Laboratory, Hospital Sant Joan de Deu, Fundación Sant Joan de Déu, Barcelona, Spain
    Mol Cancer 9:277. 2010
  3. ncbi request reprint Association between congenital cardiovascular malformations and neuroblastoma
    Rani E George
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    J Pediatr 144:444-8. 2004
  4. ncbi request reprint Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study
    Rani E George
    Department of Pediatric Hematology and Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 23:6466-73. 2005
  5. ncbi request reprint High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update
    Rani E George
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 24:2891-6. 2006
  6. pmc Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays
    Rani E George
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, United States of America
    PLoS ONE 2:e255. 2007
  7. pmc Distinct neuroblastoma-associated alterations of PHOX2B impair sympathetic neuronal differentiation in zebrafish models
    Desheng Pei
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Division of Hematology Oncology, Boston Children s Hospital, Harvard Medical School, Boston, MA, USA
    PLoS Genet 9:e1003533. 2013
  8. pmc Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a Children's Oncology Group study
    Rani E George
    Department of Pediatric Oncology, Dana Farber Cancer Institute and Children s Hospital, Boston, Massachusetts 02115, USA rani
    Pediatr Blood Cancer 55:629-38. 2010
  9. pmc Activating mutations in ALK provide a therapeutic target in neuroblastoma
    Rani E George
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nature 455:975-8. 2008
  10. pmc Activated ALK collaborates with MYCN in neuroblastoma pathogenesis
    Shizhen Zhu
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Cancer Cell 21:362-73. 2012

Collaborators

Detail Information

Publications16

  1. doi request reprint Tumor histology during induction therapy in patients with high-risk neuroblastoma
    Rani E George
    Department of Pediatric Hematology and Oncology, Dana Farber Cancer Institute and Children s Hospital, Boston, MA 02115, USA
    Pediatr Blood Cancer 59:506-10. 2012
    ..We sought to determine whether histological changes in the primary tumor following induction therapy could be used as a marker of response...
  2. pmc Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma
    Idoia Garcia
    Developmental Tumor Biology Laboratory, Hospital Sant Joan de Deu, Fundación Sant Joan de Déu, Barcelona, Spain
    Mol Cancer 9:277. 2010
    ..CHD5 gene and protein expression was reexamined after induction chemotherapy in a subset of high risk tumors to identify potential changes reflecting tumor response...
  3. ncbi request reprint Association between congenital cardiovascular malformations and neuroblastoma
    Rani E George
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    J Pediatr 144:444-8. 2004
    ..We explored the association between neuroblastoma and congenital cardiovascular malformations (CCM), previously described in case reports...
  4. ncbi request reprint Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study
    Rani E George
    Department of Pediatric Hematology and Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 23:6466-73. 2005
    ..To determine predictive strength of tumor cell ploidy and MYCN gene amplification on survival of children older than 12 months with disseminated neuroblastoma (NB)...
  5. ncbi request reprint High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update
    Rani E George
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 24:2891-6. 2006
    ..To provide an update on long-term survival of patients with high-risk neuroblastoma treated with tandem cycles of myeloablative therapy and peripheral-blood stem-cell rescue (PBSCR)...
  6. pmc Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays
    Rani E George
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, United States of America
    PLoS ONE 2:e255. 2007
    ..We analyzed paired blood and primary tumor samples from 22 children with high-risk neuroblastoma for loss of heterozygosity (LOH) and DNA copy number change using the Affymetrix 10K single nucleotide polymorphism (SNP) array...
  7. pmc Distinct neuroblastoma-associated alterations of PHOX2B impair sympathetic neuronal differentiation in zebrafish models
    Desheng Pei
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Division of Hematology Oncology, Boston Children s Hospital, Harvard Medical School, Boston, MA, USA
    PLoS Genet 9:e1003533. 2013
    ....
  8. pmc Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a Children's Oncology Group study
    Rani E George
    Department of Pediatric Oncology, Dana Farber Cancer Institute and Children s Hospital, Boston, Massachusetts 02115, USA rani
    Pediatr Blood Cancer 55:629-38. 2010
    ..We conducted a phase I trial to determine the toxicity and molecular effects of the demethylating agent, decitabine, followed by doxorubicin and cyclophosphamide in children with refractory solid tumors...
  9. pmc Activating mutations in ALK provide a therapeutic target in neuroblastoma
    Rani E George
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nature 455:975-8. 2008
    ....
  10. pmc Activated ALK collaborates with MYCN in neuroblastoma pathogenesis
    Shizhen Zhu
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Cancer Cell 21:362-73. 2012
    ..Coexpression of activated ALK with MYCN provides prosurvival signals that block this apoptotic response and allow continued expansion and oncogenic transformation of hyperplastic neuroblasts, thus promoting progression to neuroblastoma...
  11. doi request reprint Pharmacotherapy of neuroblastoma
    Rani E George
    Dana Faber Cancer Institute, Department of Pediatric Oncology, Boston, MA, USA
    Expert Opin Pharmacother 11:1467-78. 2010
    ..High risk disease in older children remains a therapeutic challenge, despite high-intensity therapy with correspondingly significant short- and long-term toxicities...
  12. pmc Emerging importance of ALK in neuroblastoma
    Anna M Azarova
    Department of Pediatric Hematology and Oncology, Dana Farber Cancer Institute and Children s Hospital Boston, Harvard Medical School, 450 Brookline Ave, Boston, MA 02115, USA
    Semin Cancer Biol 21:267-75. 2011
    ..This review addresses many of the current issues surrounding the role of ALK in normal development and neuroblastoma pathogenesis, and discusses the prospects for clinically effective targeted treatments based on ALK inhibition...
  13. pmc The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor
    Susanne Schlisio
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Genes Dev 22:884-93. 2008
    ....
  14. ncbi request reprint Neuroblastoma cells isolated from bone marrow metastases contain a naturally enriched tumor-initiating cell
    Loen M Hansford
    Cell Biology Program, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
    Cancer Res 67:11234-43. 2007
    ..These cells may serve as a model system to identify the molecular determinants of neuroblastoma and to develop new therapeutic strategies for this tumor...
  15. ncbi request reprint Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group study
    Lisa A Moreau
    The National Center for Pediatric Cancer Genetics, Children s Oncology Group, University of Florida, Gainesville, FL, USA
    Clin Cancer Res 12:5693-7. 2006
    ..The aim of this study was to determine whether children with neuroblastoma in which MYCN oncogene amplification is manifested as HSRs at diagnosis have a worse prognosis than those whose tumors exhibit dmins...
  16. ncbi request reprint Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by neuroblastoma tumors
    Sean Carlin
    Departments of Radiation Oncology and Child Health, University of Glasgow, Cancer Research UK Beatson Laboratories, Glasgow G61 1BD, United Kingdom
    Clin Cancer Res 9:3338-44. 2003
    ..EXPERMENTAL DESIGN: Tumor specimens from 54 neuroblastoma patients were analyzed using real-time PCR, and NAT expression was compared with the corresponding diagnostic scintigrams...

Research Grants2

  1. Zebrafish Peripheral Sympathetic Nervous System Development and Neuroblastoma
    RANI GEORGE; Fiscal Year: 2007
    ..Insight into the proteins encoded by such modifier genes may lead to the discovery of genes that could serve as novel drug targets for the treatment of older children with advanced disease. ..